Loading...
Loading...
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd.. Spoken Alpha tracks CANF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks CANF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 8/10 quarters with 90% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CANF.
curl https://api.spokenalpha.com/v1/companies/CANF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.07 | $2.84 | +8.1% | +5.4% | +3.5% |
| Q4 FY2026 | $3.03 | $2.88 | +5.1% | +6.0% | +3.0% |
| Q3 FY2026 | $2.69 | $2.70 | -0.2% | +5.0% | +6.9% |
| Q2 FY2026 | $2.84 | $2.69 | +5.6% | +8.1% | +5.5% |
| Q1 FY2025 | $2.93 | $2.89 | +1.5% | +5.0% | +7.7% |
| Q4 FY2025 | $3.04 | $2.95 | +2.9% | +6.3% | +9.0% |
| Q3 FY2025 | $2.81 | $2.89 | -2.7% | +5.0% | +6.2% |
| Q2 FY2025 | $3.17 | $2.96 | +7.2% | -0.3% | -1.5% |
| Q1 FY2024 | $3.25 | $3.03 | +7.3% | +9.0% | +7.2% |
| Q4 FY2024 | $2.99 | $2.99 | +0.1% | +3.5% | +4.1% |